XXII
22nd Century Group, Inc.
NASDAQ · Consumer Defensive · Tobacco · US
$0.27
+2.13%Price chart
Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21
Key dataOct 21, 2026
Open$0.26
From 52W high−99.94%
Volume645133.00
Market cap$194848.96
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataOct 21, 2026
Open
$0.26
From 52W high
−99.94%
Volume
645133.00
Market cap
$194848.96
ValuationView details →
P/E (Fwd)
0.0x
EV/EBITDA
0.4x
P/E (TTM)
—
RSI (14)
18.7
MomentumView details →
1D Return
+2.13%
YTD Return
−99.88%
SummaryUpdated Jun 1, 2026
22nd Century Group, Inc. (NASDAQ:XXII) is an agricultural biotechnology company founded in 1998 and headquartered in Buffalo, New York. The company went public in 2011 and has undergone significant strategic transformation over its history. Originally focused on developing genetically modified tobacco plants with altered nicotine content, the company expanded into hemp and cannabis biotechnology before recently divesting those operations to refocus exclusively on tobacco products. Today, 22nd Century operates as a pure-play tobacco company specializing in reduced nicotine cigarettes and contract manufacturing services for other tobacco companies.
Similar companies
Latest newsMore news →
France's ANSES recommended a maximum nicotine limit for all combustible tobacco products, a move 22nd Century Group said its reduced-nicotine tobacco platform could support.24d ago22nd Century Group urged policymakers and the FDA to enact and implement the Reduced Nicotine Content Standard, citing years without a final rule.27d agoKatherine Rouse-Bailey was appointed Vice President of Marketing at XXII, signaling a strategic shift toward brand-building and consumer engagement.61d ago